Neogenomics, Inc.
NEO
$8.75
$0.091.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.87% | -37.22% | -45.98% | -32.46% | 7.89% |
| Total Depreciation and Amortization | -7.64% | -6.51% | -4.27% | -2.34% | -1.38% |
| Total Amortization of Deferred Charges | -42.35% | -56.69% | -44.52% | -32.30% | -24.15% |
| Total Other Non-Cash Items | 63.69% | 77.70% | 81.89% | 64.61% | 19.39% |
| Change in Net Operating Assets | 39.43% | 1.64% | 17.64% | 40.17% | 23.05% |
| Cash from Operations | 194.57% | -25.53% | -8.80% | 5,221.59% | 150.15% |
| Capital Expenditure | 31.19% | 34.22% | 15.84% | -10.76% | -63.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -73.73% | -64.65% | -64.33% | -72.76% | -54.44% |
| Cash from Investing | -1,205.61% | -195.96% | -132.37% | -124.62% | -97.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -5,031,150.00% | -2,236,011.11% | -- |
| Issuance of Common Stock | -87.40% | -74.52% | -31.02% | -28.70% | 25.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 88.16% | 100.00% | -39.47% | -50.90% | -39.47% |
| Cash from Financing | -4,317.93% | -4,410.98% | -3,925.44% | -3,487.41% | 19.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,500.92% | -945.68% | -454.91% | -403.53% | -74.64% |